Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines

A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambrosino, Donna, Han, Htay Htay, Hu, Branda, Liang, Joshua, Clemens, Ralf, Johnson, Marina, Siber, George, Goldblatt, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Articles and Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763959/
https://www.ncbi.nlm.nih.gov/pubmed/34888662
http://dx.doi.org/10.1093/infdis/jiab574
_version_ 1784634063854764032
author Ambrosino, Donna
Han, Htay Htay
Hu, Branda
Liang, Joshua
Clemens, Ralf
Johnson, Marina
Siber, George
Goldblatt, David
author_facet Ambrosino, Donna
Han, Htay Htay
Hu, Branda
Liang, Joshua
Clemens, Ralf
Johnson, Marina
Siber, George
Goldblatt, David
author_sort Ambrosino, Donna
collection PubMed
description A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines.
format Online
Article
Text
id pubmed-8763959
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-87639592022-01-19 Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines Ambrosino, Donna Han, Htay Htay Hu, Branda Liang, Joshua Clemens, Ralf Johnson, Marina Siber, George Goldblatt, David J Infect Dis Major Articles and Brief Reports A significant correlation has been shown between the binding antibody responses against original severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and vaccine efficacy of 4 approved coronavirus disease 2019 vaccines. We therefore assessed the immune response against original SARS-CoV-2 elicited by the adjuvanted S-Trimer vaccine, SCB-2019 + CpG/alum, in the same assay and laboratory. Responses to SCB-2019 were comparable or superior for antibody to original and Alpha variant when compared with 4 approved vaccines. The comparison accurately predicted success of the recently reported efficacy trial of SCB-2019 vaccine. Immunogenicity comparisons to original strain and variants of concern should be considered as a basis for authorization of vaccines. Oxford University Press 2021-11-19 /pmc/articles/PMC8763959/ /pubmed/34888662 http://dx.doi.org/10.1093/infdis/jiab574 Text en © The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Articles and Brief Reports
Ambrosino, Donna
Han, Htay Htay
Hu, Branda
Liang, Joshua
Clemens, Ralf
Johnson, Marina
Siber, George
Goldblatt, David
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
title Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
title_full Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
title_fullStr Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
title_full_unstemmed Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
title_short Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
title_sort immunogenicity of scb-2019 coronavirus disease 2019 vaccine compared with 4 approved vaccines
topic Major Articles and Brief Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763959/
https://www.ncbi.nlm.nih.gov/pubmed/34888662
http://dx.doi.org/10.1093/infdis/jiab574
work_keys_str_mv AT ambrosinodonna immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT hanhtayhtay immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT hubranda immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT liangjoshua immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT clemensralf immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT johnsonmarina immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT sibergeorge immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines
AT goldblattdavid immunogenicityofscb2019coronavirusdisease2019vaccinecomparedwith4approvedvaccines

Ejemplares similares